Total Payments
$1.3M
2021 Payments
$263,678
Companies
26
Transactions
1,203
Medicare Patients
520
Medicare Billing
$57,809
Payment Breakdown by Category
Other$850,519 (64.7%)
Consulting$271,280 (20.6%)
Travel$166,580 (12.7%)
Food & Beverage$22,126 (1.7%)
Research$4,930 (0.4%)
Education$0.29 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $803,463 | 290 | 61.1% |
| Consulting Fee | $271,280 | 91 | 20.6% |
| Travel and Lodging | $166,580 | 424 | 12.7% |
| Honoraria | $47,056 | 21 | 3.6% |
| Food and Beverage | $22,126 | 369 | 1.7% |
| Unspecified | $4,930 | 7 | 0.4% |
| Education | $0.29 | 1 | 0.0% |
Payments by Type
General
$1.3M
1,196 transactions
Research
$4,930
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $375,046 | 302 | $0 (2021) |
| Pharmacyclics LLC, An AbbVie Company | $176,435 | 226 | $0 (2019) |
| Kite Pharma, Inc. | $156,437 | 140 | $0 (2021) |
| Incyte Corporation | $111,360 | 95 | $0 (2021) |
| Gilead Sciences, Inc. | $75,215 | 73 | $0 (2019) |
| Janssen Global Services, LLC | $54,757 | 38 | $0 (2018) |
| Celgene Corporation | $46,245 | 37 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $44,993 | 30 | $0 (2020) |
| Janssen Biotech, Inc. | $42,283 | 71 | $0 (2021) |
| Epizyme, Inc., | $41,453 | 39 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $263,678 | 214 | AstraZeneca Pharmaceuticals LP ($88,671) |
| 2020 | $227,521 | 140 | AstraZeneca Pharmaceuticals LP ($88,152) |
| 2019 | $234,969 | 214 | AstraZeneca Pharmaceuticals LP ($92,185) |
| 2018 | $321,142 | 340 | AstraZeneca Pharmaceuticals LP ($92,273) |
| 2017 | $268,125 | 295 | Pharmacyclics LLC, An AbbVie Company ($105,656) |
All Payment Transactions
1,203 individual payment records from CMS Open Payments — Page 1 of 49
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2021 | Janssen Biotech, Inc. | DARZALEX (Biological), IMBRUVICA | Food and Beverage | In-kind items and services | $10.48 | General |
| Category: Oncology | ||||||
| 12/09/2021 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $124.89 | General |
| 12/08/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,750.00 | General |
| Category: Oncology | ||||||
| 12/01/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,500.00 | General |
| Category: Oncology | ||||||
| 12/01/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,050.00 | General |
| Category: Oncology | ||||||
| 12/01/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,050.00 | General |
| Category: Oncology | ||||||
| 12/01/2021 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $17.97 | General |
| Category: CELLT | ||||||
| 11/19/2021 | Kite Pharma, Inc. | Yescarta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,420.00 | General |
| Category: CELLT | ||||||
| 11/18/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $522.04 | General |
| Category: Oncology | ||||||
| 11/18/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $210.90 | General |
| Category: Oncology | ||||||
| 11/18/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $105.06 | General |
| Category: Oncology | ||||||
| 11/18/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $91.18 | General |
| Category: Oncology | ||||||
| 11/18/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Travel and Lodging | In-kind items and services | $83.68 | General |
| Category: Oncology | ||||||
| 11/18/2021 | TG Therapeutics, Inc. | UKONIQ (Drug) | — | Cash or cash equivalent | $15.58 | Research |
| Study: UTXTGR205 • Category: Hematology | ||||||
| 11/17/2021 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $663.80 | General |
| Category: CELLT | ||||||
| 11/17/2021 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $340.36 | General |
| Category: CELLT | ||||||
| 11/17/2021 | Kite Pharma, Inc. | Yescarta (Drug) | Travel and Lodging | In-kind items and services | $254.80 | General |
| Category: CELLT | ||||||
| 11/17/2021 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $86.09 | General |
| Category: CELLT | ||||||
| 11/16/2021 | Kite Pharma, Inc. | — | Food and Beverage | In-kind items and services | $12.05 | General |
| 11/04/2021 | Kite Pharma, Inc. | Yescarta (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,890.00 | General |
| Category: CELLT | ||||||
| 11/03/2021 | Incyte Corporation | MONJUVI (Drug) | Travel and Lodging | Cash or cash equivalent | $491.50 | General |
| Category: Oncology | ||||||
| 10/27/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: Oncology | ||||||
| 10/24/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,500.00 | General |
| Category: Oncology | ||||||
| 10/24/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,500.00 | General |
| Category: Oncology | ||||||
| 10/24/2021 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AZA-MDS-006 | Celgene Corporation | $2,976 | 2 |
| A PHASE IBII STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH IDASANUTLIN IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA AND OBINUTUZUMAB OR RITUXIMAB IN COMBINATION WITH IDASANUTLIN IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA | F. Hoffmann-La Roche AG | $1,065 | 2 |
| Treatment Patterns Outcomes and Patient Reported Quality of Life A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents | AstraZeneca Pharmaceuticals LP | $523.62 | 1 |
| PCYC-1134M-CA | Pharmacyclics LLC, An AbbVie Company | $350.00 | 1 |
| UTXTGR205 | TG Therapeutics, Inc. | $15.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 5 | 273 | 413 | $106,310 | $32,388 |
| 2020 | 5 | 247 | 365 | $97,422 | $25,421 |
Total Patients
520
Total Services
778
Medicare Billing
$57,809
Procedure Codes
10
All Medicare Procedures & Services
10 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 154 | 249 | $62,499 | $18,702 | 29.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 44 | 60 | $21,120 | $6,484 | 30.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 25 | 25 | $11,775 | $3,517 | 29.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 21 | 44 | $8,536 | $2,742 | 32.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 29 | 35 | $2,380 | $942.72 | 39.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 106 | 150 | $35,850 | $8,267 | 23.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 76 | 96 | $32,160 | $8,026 | 25.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 22 | 75 | $14,400 | $4,744 | 32.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 22 | 22 | $9,878 | $3,017 | 30.5% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 21 | 22 | $5,134 | $1,367 | 26.6% |
About John Pagel, MD PHD
John Pagel, MD PHD is a Hematology & Oncology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/13/2006. The National Provider Identifier (NPI) number assigned to this provider is 1376633222.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, John Pagel, MD PHD has received a total of $1.3M in payments from pharmaceutical and medical device companies, with $263,678 received in 2021. These payments were reported across 1,203 transactions from 26 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($803,463).
As a Medicare-enrolled provider, Pagel has provided services to 520 Medicare beneficiaries, totaling 778 services with total Medicare billing of $57,809. Data is available for 2 years (2020–2021), covering 10 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Seattle, WA
- Active Since 10/13/2006
- Last Updated 06/22/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1376633222
Products in Payments
- CALQUENCE (Drug) $373,239
- Imbruvica (Drug) $176,085
- MONJUVI (Drug) $114,435
- Yescarta (Drug) $112,692
- IMBRUVICA (Drug) $78,370
- Zydelig (Drug) $74,160
- NINLARO (Drug) $63,575
- TAZVERIK (Drug) $41,453
- BRUKINSA (Drug) $41,303
- DARZALEX (Biological) $31,135
- Revlimid (Drug) $29,618
- ADCETRIS (Biological) $28,882
- Copiktra (Drug) $13,357
- clonoSEQ (Device) $12,030
- Tecartus (Drug) $9,700
- Non-Covered $8,654
- SGN35 (Biological) $5,934
- Zevalin (Drug) $5,005
- BENDEKA (Drug) $4,109
- JCAR017 (Drug) $3,390
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Seattle
Mr. John Pesando, Md, MD
Hematology & Oncology — Payments: $12.8M
Hematology & Oncology $12.8M
Dr. Langdon Miller, Md, MD
Hematology & Oncology — Payments: $674,815
Hematology & Oncology $674,815
Dr. Vijayakrishna Gadi, M.d. Phd, M.D. PHD
Hematology & Oncology — Payments: $534,649
Hematology & Oncology $534,649
Barbara Konkle, Md, MD
Hematology & Oncology — Payments: $331,390
Hematology & Oncology $331,390
Dr. Jill Johnsen, Md, MD
Hematology & Oncology — Payments: $291,732
Hematology & Oncology $291,732
Dr. Rebecca Kruse-Jarres, M.d, M.D
Hematology & Oncology — Payments: $288,284
Hematology & Oncology $288,284